UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
Urogen Pharma $URGN Shares Bought by Truist Financial Corp
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally
Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Thursday
UroGen: Expect Rough Patch Before Strong Recovery In 2026
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma to Present at Upcoming Investor Conferences
Piper starts 'underestimated' UroGen Pharma with an Overweight
UroGen Pharma: Targeting Profits In 2027
UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025